Amylin receptor agonist: difference between revisions
Diff·revision 6 → 7·10:10, 2 Dec 2024
Difference between revision 6 and revision 7 of Amylin receptor agonist. 2 lines changed; the page grew by 334 bytes.
| Revision 6 — 07:50, 16 Nov 2024 ParentCatPansy (talk) label the animal data as animal data in the sentence, not only in the section heading 2,571 bytes +35 | Revision 7 — 10:10, 2 Dec 2024 ExenatideEzra (talk) split overlong sentence 2,905 bytes +334 | ||
|---|---|---|---|
| 17 | Pramlintide takes the rodent solution: rat amylin does not aggregate because prolines at three positions in the central region prevent β-sheet stacking, and pramlintide introduces those substitutions into the human sequence. The result is soluble and stable but retains a short half-life of about 48 minutes, and its acidic formulation cannot be mixed in a syringe with insulin. | 17 | Pramlintide takes the rodent solution: rat amylin does not aggregate because prolines at three positions in the central region prevent β-sheet stacking, and pramlintide introduces those substitutions into the human sequence. The result is soluble and stable but retains a short half-life of about 48 minutes, and its acidic formulation cannot be mixed in a syringe with insulin. |
| 18 | 18 | ||
| + | 19 | Cagrilintide adds acylation for [[Albumin binding half-life extension|albumin binding]], reaching a half-life supporting weekly administration. It engages the calcitonin receptor as well as the amylin receptors, and whether that broader engagement contributes to or detracts from the clinical effect is not established.{{r|lau2021}} | |
| + | 20 | ||
| 19 | == References == | 21 | == References == |
| 20 | {{reflist}} | 22 | {{reflist}} |